TrialOncotarget2015

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Otto Hemminki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.